XYLOCAINE VISCOUS 2% SOLUTION

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Aktīvā sastāvdaļa:

LIDOCAINE HYDROCHLORIDE

Pieejams no:

ASPEN PHARMACARE CANADA INC.

ATĶ kods:

N01BB02

SNN (starptautisko nepatentēto nosaukumu):

LIDOCAINE

Deva:

20MG

Zāļu forma:

SOLUTION

Kompozīcija:

LIDOCAINE HYDROCHLORIDE 20MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

100ML

Receptes veids:

Ethical

Ārstniecības joma:

LOCAL ANESTHETICS

Produktu pārskats:

Active ingredient group (AIG) number: 0101280001; AHFS:

Autorizācija statuss:

APPROVED

Autorizācija datums:

2000-05-11

Produkta apraksts

COPYRIGHT 1958 – 2018 ASTRAZENECA CANADA INC.
Page 1 of 22
_ _
_ _
_ _
PRESCRIBING INFORMATION
XYLOCAINE
® VISCOUS 2%
(lidocaine hydrochloride solution)
20 mg/mL
Oral Topical Anesthetic
Aspen Pharmacare Canada Inc.
111 Queen Street East, Suite 450
Toronto, Ontario
M5C 1S2
Date of Revision:
July 12, 2018
Submission Control No.: 216864
XYLOCAINE
®
is a registered trademark of the AstraZeneca group of companies.
COPYRIGHT 1958 – 2018 ASTRAZENECA CANADA INC.
Page 2 of 22
TABLE OF CONTENTS
PRESCRIBING INFORMATION
...........................................................................................
1
TABLE OF CONTENTS
.........................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................... 3
SUMMARY PRODUCT INFORMATION
......................................................................
3
INDICATIONS AND CLINICAL USE
...........................................................................
3
CONTRAINDICATIONS
.................................................................................................
4
WARNINGS AND PRECAUTIONS
...............................................................................
4
ADVERSE REACTIONS
.................................................................................................
8
DRUG INTERACTIONS
.................................................................................................
9
DOSAGE AND ADMINISTRATION
...........................................................................
11
OVERDOSAGE
..............................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
.......................................................... 14
STORAGE AND STABILITY
.......................................................................................
16
DOSAGE FORMS, COMPOSITION AND PACKAGING
........................................... 16
REFERENCES
.....